Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, reviews the rationale for capivasertib in hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results